Does Wilms Tumour-1 Gene Mutation Affect Treatment Options and Response in Acute Myeloid Leukaemia?

YILMAZ S., Zorlu T., Cırık S., Hidayet E., Durdu A., Okumuş N., ...Daha Fazla

Acta Haematologica Oncologica Turcica, cilt.58, sa.1, ss.16-20, 2025 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.4274/ahot.galenos.2024.2024-9-2
  • Dergi Adı: Acta Haematologica Oncologica Turcica
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.16-20
  • Anahtar Kelimeler: Acute myeloid leukemia, prognosis, WT-1 mutations
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aim: The prognostic impact of Wilms tumour-1 (WT-1) mutations is controversial for patients with acute myeloid leukaemia (AML). In this study, we aimed to determine the clinical effects of WT-1 mutations. Methods: We retrospectively analysed the data of a total of 139 patients with AML, 50 negative and 89 positive, in whom WT-1 analysis was performed at the time of diagnosis. Results: Among the patients, 47% were female and 53% were male; median age was 62 (18-88) years in the WT-1 negative group and 47 (18-90) years in the WT-1 positive group; median follow-up period was 5 (1-144) months in the WT-1 negative group and 28 (1-110) months in the WT-1 positive group. When the induction treatments were analysed, the regimen containing idarubicin and cytarabine was the most commonly used regimen in both groups (73% in the WT-1 positive group and 36% in the WT-1 negative group). When the response to treatment was evaluated in WT-1-negative and positive groups, complete response was 58% to 80% for WT-1-negative and positive groups respectively; partial response was 14% to 2%; refractoriness was 26% to 16%, respectively. Recurrence was 16% in the WT-1 negative group and 5.6% in the positive group. The survival rate was found to be 64% in the WT-1 negative group and 67.4% in the positive group. Conclusion: It is uncertain whether the WT-1 test will be interpreted in diagnosis, treatment, and follow-up, or if its prognostic significance and future studies are much needed.